A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

However, among the experimental biomarkers, it should be noted that baseline levels of BSP were moderately associated with duration of bone metastases, and were also associated with failure to complete the study despite the fact that BSP did not reach statistical significance for an association with incidence of on-study SRE.

also in 111,027 other papers